Physician profile
Michael J Labellarte
NPI 1659568137
$92,204.45
in general payments reported to CMS, 2019-2025
21 companies · $20K in 2025
The $20K reported for 2025 was more than what 98% of Child & Adolescent Psychiatry providers received nationally (typical 2025 total: $132).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,859 · 2020: $218 · 2021: $20K · 2022: $1,694 · 2023: $35K · 2024: $13K · 2025: $20K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $37K · Honoraria: $21K · Travel and Lodging: $5,020 · Food and Beverage: $4,725 · Consulting Fee: $240.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $37,460.00 |
| Honoraria | $20,550.00 |
| Travel and Lodging | $5,019.82 |
| Food and Beverage | $4,725.48 |
| Consulting Fee | $240.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Supernus Pharmaceuticals, INC. | $86,731.72 | 2019-2025 | Qelbree, Qelbree |
| Corium, LLC | $1,980.91 | 2022-2025 | Azstarys |
| Takeda Pharmaceuticals U.S.A., INC. | $1,005.64 | 2019-2025 | Trintellix |
| Lundbeck LLC | $460.26 | 2019-2025 | Rexulti |
| Otsuka America Pharmaceutical, INC. | $439.82 | 2019-2025 | Rexulti |
| Janssen Pharmaceuticals, INC | $367.92 | 2019 | |
| Neos Therapeutics, Lp | $284.47 | 2019-2023 | Adzenys Xr-Odt |
| Ironshore Pharmaceuticals INC. | $190.16 | 2023-2024 | Jornay Pm |
| Shire North American Group INC | $123.02 | 2019 | |
| Vertical Pharmaceuticals, LLC | $122.80 | 2024-2025 | Relexxii |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $87.49 | 2022-2025 | Caplyta |
| Tris Pharma INC | $76.10 | 2024-2025 | Dyanavel Xr |
| Abbvie INC. | $64.39 | 2022-2025 | |
| Owp Pharmaceuticals, INC. | $58.50 | 2019 | |
| Alkermes, INC. | $43.04 | 2022 |
Show all 21 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Allergan, INC. | $37.94 | 2019 | |
| Noven Therapeutics, LLC | $37.27 | 2024 | Xelstrym |
| Axsome Therapeutics, INC. | $34.48 | 2022 | |
| Adlon Therapeutics L.P. | $27.54 | 2020 | |
| Collegium Pharmaceutical, INC. | $18.30 | 2025 | Jornay Pm |
| Tms Neurohealth Centers INC. | $12.68 | 2025 | Tms Neurohealth Centers INC. |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Michael Labellarte listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.